This synthetic lethality—a phenomenon where multiple, concurrent genetic events lead to cell apoptosis rather than a single event—allows the increased sensitivity of BRCA-mutated tumours to PARP inhibitors and is a novel approach that has changed the treatment of ovarian cancer [52,53]. Here, PARP1 is linked to ovarian carcinoma.